Monte Rosa's MRT-2359 Enters Phase 2 for Prostate Cancer with J&J Apalutamide Supply
Summary
Monte Rosa Therapeutics announced a clinical supply agreement with Johnson & Johnson to evaluate its investigational drug, MRT-2359, in combination with J&J's ERLEADA® (apalutamide) for metastatic castration-resistant prostate cancer (mCRPC). This agreement facilitates a planned Phase 2 study, expected to initiate in Q3 2026, focusing on patients with AR mutations. The company noted compelling clinical activity observed in an ongoing Phase 1/2 study, indicating this combination approach holds significant promise and could position the program for future registrational studies. This represents a material positive step for Monte Rosa's lead pipeline asset, advancing its development and providing access to a key combination therapy. Traders will monitor the initiation of the Phase 2 trial and subsequent data readouts.
At the time of this announcement, GLUE was trading at $16.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.50 to $25.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.